Evidence map›Paper›PMID 30885249›Full record

ArticleStem cell research & therapy2019

Human bone marrow mesenchymal stem cells-derived exosomes alleviate liver fibrosis through the Wnt/β-catenin pathway.

Xiaoli Rong, Junzhi Liu, Xia Yao, Tiechao Jiang, Yimin Wang, Feng Xie

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cell research & therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 205 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
205citing papers in PubMed, 2 pooled it
21.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

205 citing papers in PubMed, 2 syntheses or guidelines pooled it, 314 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Biology and Therapeutic Potential of Exosomes, Targeted Drug Delivery.International journal of molecular sciences · 2026
    Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Exosomes in ocular graft-versus-host disease: an overview.International journal of ophthalmology · 2026
    Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review

145 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Xiaoli RongDepartment of Clinical Laboratory, China-Japan Union Hospital of Jilin University, 126 Xiantai St., Changchun, 130033, Jilin, China.
Junzhi LiuDepartment of Quality Control, China-Japan Union Hospital of Jilin University, 126 Xiantai St., Changchun, 130033, Jilin, China.
Xia YaoDepartment of Anesthesiology, Affiliated Hospital of Changchun University of Traditional Chinese Medicine, 1478 Gongnong Road, Changchun, 130117, Jilin, China.
Tiechao JiangDepartment of Cardiology, China-Japan Union Hospital of Jilin University, 126 Xiantai St., Changchun, 130033, Jilin, China.
Yimin WangThe Scientific Research Center, China-Japan Union Hospital of Jilin University, 126 Xiantai St., Changchun, 130033, Jilin, China. yiminwang@hotmail.com.
Feng XieDepartment of Clinical Laboratory, China-Japan Union Hospital of Jilin University, 126 Xiantai St., Changchun, 130033, Jilin, China. xiefeng1962@hotmail.com.ORCID 0000-0003-1091-5848
Union Hospital · CNChangchun University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMesenchymal stem cells (MSCs) are increasingly being applied as a therapy for liver fibrosis. Exosomes possess similar functions to their parent cells; however, they are safe and effective cell-free reagents with controllable and predictable outcomes. In this study, we investigated the therapeutic potential and underlying molecular mechanism for human bone mesenchymal stem cells-derived exosomes (hBM-MSCs-Ex) in the treatment of liver fibrosis.

methodsWe established an 8-week CCl

resultsIn vivo administration of hBM-MSCs-Ex effectively alleviated liver fibrosis, including a reduction in collagen accumulation, enhanced liver functionality, inhibition of inflammation, and increased hepatocyte regeneration. Moreover, based on measurement of the collagen area, Ishak fibrosis score, MDA levels, IL-1, and IL-6, the therapeutic effect of hBM-MSCs-Ex against liver fibrosis was significantly greater than that of hBM-MSCs. In addition, we found that hBM-MSCs-Ex inhibited the expression of Wnt/β-catenin pathway components (PPARγ, Wnt3a, Wnt10b, β-catenin, WISP1, Cyclin D1), α-SMA, and Collagen I, in both HSCs and liver fibrosis tissue.

conclusionsThese results suggest that hBM-MSCs-Ex treatment could ameliorate CCl

Indexed as

Carbon Tetrachloride PoisoningExosomesLiver CirrhosisWnt Signaling PathwayAnimalsbeta CateninBone Marrow CellsFemaleHeterograftsHumansMesenchymal Stem CellsRatsRats, Sprague-Dawleybeta CateninExosomeshBM-MSCsLiver fibrosisWnt/β-catenin

Identifiers

PMID30885249
PMCPMC6421647
OpenAlexW2924673089

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.